Sab Biotherapeutics
(NASDAQ) SABS
Sab Biotherapeutics Financials at a Glance
Market Cap
$197.18M
Revenue (TTM)
$0.00
Net Income (TTM)
$13.27M
EPS (TTM)
$-2.67
P/E Ratio
-1.45
Dividend
$0.00
Beta (Volatility)
0.63 (Low)
Dividend
$0.00
Beta (Volatility)
0.63 (Low)
Price
$3.87
Volume
3,307
Open
$3.87
Price
$3.87
Volume
3,307
Open
$3.87
Previous Close
$3.87
Daily Range
$3.83 - $3.96
52-Week Range
$1.00 - $6.60
Dividend
$0.00
Beta (Volatility)
0.63 (Low)
Price
$3.87
Volume
3,307
Open
$3.87
Previous Close
$3.87
Daily Range
$3.83 - $3.96
52-Week Range
$1.00 - $6.60
SABS News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Sab Biotherapeutics
Industry
Biotechnology
Sector
Health CareEmployees
86
CEO
Samuel J. Reich
Website
www.sab.bioHeadquarters
Sioux Falls, SD 57104, US
SABS Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-14%
Return on Capital
-30%
Return on Assets
8%
Earnings Yield
-68.97%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$197.18M
Shares Outstanding
50.95M
Volume
3.31K
Short Interest
0.00%
Avg. Volume
581.87K
Financials (TTM)
Gross Profit
$3.08M
Operating Income
$48.95M
EBITDA
$16.60M
Operating Cash Flow
$44.78M
Capital Expenditure
$933.15K
Free Cash Flow
$45.71M
Cash & ST Invst.
$96.59M
Total Debt
$5.95M
Sab Biotherapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
-100.0%
Gross Profit
$763.30K
-13.8%
Gross Margin
0.00%
N/A
Market Cap
$197.18M
N/A
Market Cap/Employee
$3.13M
N/A
Employees
63
N/A
Net Income
$16.86M
-48.0%
EBITDA
$16.03M
-52.2%
Quarterly Fundamentals
Net Cash
$90.64M
+463.3%
Accounts Receivable
$946.78K
+1622.8%
Inventory
$0.00
N/A
Long Term Debt
$5.00M
+29.6%
Short Term Debt
$951.37K
+17.2%
Return on Assets
7.68%
N/A
Return on Invested Capital
-30.19%
N/A
Free Cash Flow
$17.71M
-89.9%
Operating Cash Flow
$16.78M
-81.0%